Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Total Non-Current Liabilities (2016 - 2025)

Collegium Pharmaceutical has reported Total Non-Current Liabilities over the past 6 years, most recently at $1.4 billion for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $1.4 billion for Q4 2025, down 5.47% from a year ago — trailing twelve months through Dec 2025 was $1.4 billion (down 5.47% YoY), and the annual figure for FY2025 was $1.4 billion, down 5.47%.
  • Total Non-Current Liabilities for Q4 2025 was $1.4 billion at Collegium Pharmaceutical, up from $1.3 billion in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for COLL hit a ceiling of $1.4 billion in Q4 2024 and a floor of $947.9 million in Q4 2023.
  • Median Total Non-Current Liabilities over the past 3 years was $1.4 billion (2025), compared with a mean of $1.3 billion.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 51.24% in 2024 and later dropped 5.47% in 2025.
  • Collegium Pharmaceutical's Total Non-Current Liabilities stood at $947.9 million in 2023, then surged by 51.24% to $1.4 billion in 2024, then fell by 5.47% to $1.4 billion in 2025.
  • The last three reported values for Total Non-Current Liabilities were $1.4 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.4 billion (Q2 2025) per Business Quant data.